LoginSignup
Biogen logo

Biogen

Stock
Stock
ISIN: US09062X1037
Ticker: BIIB
US09062X1037
BIIB

Price

Price

Frequently asked questions

What is Biogen's market capitalization?

The market capitalization of Biogen is $23.03B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Biogen's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Biogen is 14.28. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Biogen?

Biogen's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $11.07. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Biogen's stock?

Currently, 36 analysts cover Biogen's stock, with a consensus target price of $279.93. Analyst ratings provide insights into the stock's expected performance.

What is Biogen's revenue over the trailing twelve months?

Over the trailing twelve months, Biogen reported a revenue of $9.61B.

What is the EBITDA for Biogen?

Biogen's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $3.14B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Biogen?

Biogen has a free cash flow of $1.77B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Biogen's stock?

The 5-year beta for Biogen is -0.08. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Biogen have, and what sector and industry does it belong to?

Biogen employs approximately 7,570 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Biogen's shares?

The free float of Biogen is 145.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $23.03B

5Y beta

 -0.08

EPS (TTM)

 $11.07

Free Float

 145.50M

P/E ratio (TTM)

 14.28

Revenue (TTM)

 $9.61B

EBITDA (TTM)

 $3.14B

Free Cashflow (TTM)

 $1.77B

Pricing

1D span
$156.75$159.26
52W span
$153.62$268.30

Analyst Ratings

The price target is $279.93 and the stock is covered by 36 analysts.

Buy

22

Hold

14

Sell

0

Information

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

7,570

Biotechnology & Drugs

Health Care

Identifier

ISIN

US09062X1037

Primary Ticker

BIIB

Knockouts

Join the conversation
Sign upLogin